Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | SVP & Pres, Neuromodulation | February 28, 2022 | March 02, 2022 |
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director | May 28, 2025 | May 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,258 |
Ending reported balance
After 2022-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-28 · Exercise / conversion · Acquired 1,630 · Balance 177,822 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2022-02-28 · Tax withholding · Disposed 564 · Balance 177,258 |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2022-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-28 · Exercise / conversion · Disposed 1,630 · Balance 0 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Rani Therapeutics Holdings, Inc.
Report date May 28, 2025 · Filed May 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2035-05-27 | Direct | 50,000 |
Reported balance
After 2025-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2019 Filed Dec 5, 2019 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 9,623 | $13.08 | $125,868.84 |
DisclosureSEC source: 0001225208-19-015300 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,552 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-19-015054 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,851 Underlying: Common Stock · 20,552 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 20,552 | $43.27 | $889,322.03 |
DisclosureSEC source: 0001225208-19-015054 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,194 F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.27 to $43.28, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 20,552 | $17.26 | $354,727.52 |
DisclosureSEC source: 0001225208-19-015054 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 21:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,623 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-19-014138 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,630 Underlying: Common Stock · 9,623 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 21:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 9,623 | $41.66 | $400,894.18 |
DisclosureSEC source: 0001225208-19-014138 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,194 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 21:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 9,623 | $13.08 | $125,868.84 |
DisclosureSEC source: 0001225208-19-014138 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,623 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-19-013232 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,253 Underlying: Common Stock · 9,623 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 9,623 | $39.25 | $377,744.13 |
DisclosureSEC source: 0001225208-19-013232 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,194 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.44, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 9,623 | $13.08 | $125,868.84 |
DisclosureSEC source: 0001225208-19-013232 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,035 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-19-012044 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,035 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 34,035 | $42.65 | $1,451,422.58 |
DisclosureSEC source: 0001225208-19-012044 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,194 F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.51 to $42.75, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 34,035 | $7.39 | $251,518.65 |
DisclosureSEC source: 0001225208-19-012044 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 20:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,039 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-009372 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,039 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual increments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 20:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,039 | $40.46 | $122,957.94 |
DisclosureSEC source: 0001225208-19-009372 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,469 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 20:23 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,039 | $7.41 | $22,518.99 |
DisclosureSEC source: 0001225208-19-009372 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 15, 2019 Filed May 16, 2019 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,038 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-008111 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,039 Underlying: Common Stock · 3,038 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual increments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| May 15, 2019 Filed May 16, 2019 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,038 | $36.74 | $111,616.12 |
DisclosureSEC source: 0001225208-19-008111 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,469 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 15, 2019 Filed May 16, 2019 20:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,038 | $7.41 | $22,511.58 |
DisclosureSEC source: 0001225208-19-008111 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 20:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,039 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-006846 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,077 Underlying: Common Stock · 3,039 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual increments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 20:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,039 | $37.81 | $114,904.59 |
DisclosureSEC source: 0001225208-19-006846 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,469 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 20:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,039 | $7.41 | $22,518.99 |
DisclosureSEC source: 0001225208-19-006846 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 20:22 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,038 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-005415 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,116 Underlying: Common Stock · 3,038 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual increments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 20:22 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,038 | $40.11 | $121,854.18 |
DisclosureSEC source: 0001225208-19-005415 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,469 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 20:22 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,038 | $7.41 | $22,511.58 |
DisclosureSEC source: 0001225208-19-005415 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004350 · doc4.xml · derivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,888 Underlying: Common Stock · 1,629 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 808 | $40.12 | $32,416.96 |
DisclosureSEC source: 0001225208-19-004350 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,469 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004350 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 25, 2019 Filed Mar 4, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 1,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004350 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,648 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003741 · doc4.xml · derivative · entry 9 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,676 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,327 | $40.52 | $53,770.04 |
DisclosureSEC source: 0001225208-19-003741 · doc4.xml · nonDerivative · entry 6 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,348 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003741 · doc4.xml · nonDerivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003741 · doc4.xml · derivative · entry 8 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,840 Underlying: Common Stock · 1,839 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 912 | $40.52 | $36,954.24 |
DisclosureSEC source: 0001225208-19-003741 · doc4.xml · nonDerivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,999 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003741 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003741 · doc4.xml · derivative · entry 7 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,766 Underlying: Common Stock · 1,883 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 934 | $40.52 | $37,845.68 |
DisclosureSEC source: 0001225208-19-003741 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,072 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003741 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:41 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 22,195 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003569 · doc4.xml · derivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,195 Underlying: Common Stock · 22,195 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:41 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 6,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003569 · doc4.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock · 6,854 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 9,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003443 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,791 Underlying: Common Stock · 9,791 shares Expires 2020-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F4 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F4 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F4 · balance_after: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 7,959 | $40.11 | $319,235.49 |
DisclosureSEC source: 0001225208-19-003443 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,123 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 18,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003443 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,082 F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2018 and subject to the completion of the concurrent three-year individual service period. On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,039 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-002987 · doc4.xml · derivative · entry 6 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,154 Underlying: Common Stock · 3,039 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four annual increments beginning on February 16, 2011, the first anniversary of the grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002987 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,644 Underlying: Common Stock · 1,661 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,039 | $40.32 | $122,532.48 |
DisclosureSEC source: 0001225208-19-002987 · doc4.xml · nonDerivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,254 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 575 | $40.01 | $23,005.75 |
DisclosureSEC source: 0001225208-19-002987 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,293 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002987 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,039 | $7.41 | $22,518.99 |
DisclosureSEC source: 0001225208-19-002987 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,038 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-000883 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,193 Underlying: Common Stock · 3,038 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four annual increments beginning on February 16, 2011, the first anniversary of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.